Sponsors Gear Up For a Smoother Process With CTIS but Must First Overcome Key Hurdles

Posted by Milena Shuytsova-Mircheva and Lisa Pascoe | Jun 21, 2022 6:58:27 PM

Read the latest blog from our Pharmalex colleagues, Milena Shuytsova-Mircheva and Lisa Pascoe, who discuss the benefit of the Clinical Trial Information System (CTIS).  

 

Companies have one year to prepare for the CTIS

The Clinical Trial Information System (CTIS) went live at the end of January and serves as the single-entry point for clinical trial data under the Clinical Trials Regulation (CTR) within the European Union and European Economic Area (EEA) countries. Companies have one year to prepare for the CTIS, after which any new application must be submitted via the CTIS.

 

The CTIS will simplify the application process considerably by allowing sponsors to apply for clinical trial authorization in up to 30 EEA countries with the single application. In particular, using an organization-centric approach, as recommended by the European Medicines Agency (EMA), will allow sponsors to oversee their trials.

 

Harmonization, transparency and consistency

For both sponsors and regulators, the CTIS will harmonize the application and assessment process, improve collaboration and information-sharing between member states and sponsors, increase transparency and the consistency and reliability of information, simplify safety reporting and enhance safety standards for clinical trial participants.

 

While there are immense benefits for sponsors and regulators, there are many hurdles to overcome. The CTIS requires companies to develop a user management model, however, access rights could become an issue in a variety of situations. These include:

  • If identified users leave the company or CRO
  • If a user doesn’t have access to the CTIS training environment, called CTIS Sandbox, they might struggle to adapt their internal processes
  • If a sponsor works with several CROs they may need to limit access rights to ensure each CRO only has access to documentation for the trial they’re working on

Another key challenge to be aware of is the need to respond to any request for information in the 12-day timeline or risk the trial lapsing. To avoid this problem, companies need a dedicated person to check the system regularly since it doesn’t send automatic notifications to sponsors.

 

The CTIS does not allow parallel submissions, so if there are requests for substantial modifications while another assessment is ongoing, companies will have to wait, and that could impact the timing of a clinical trial. There are also issues with parallel submissions for multinational trials when documents must be provided in local languages. In these situations, companies are advised to determine whether they want to submit part 1 (the scientific and medicinal product document) and part 2 (the national and patient-level documentation) simultaneously or separately, and whether there are any additional considerations regarding which countries to submit to first.

 

As with all new systems the time and costs associated with training are inevitably a burden for the organization, but it’s important to ensure training of not only CTIS users but also management to ensure at least a basic understanding of the new processes.

 

Preparing for a new approach

Many companies are updating their internal processes to align with specific user roles; however, accessing the training environment remains a priority since this will be key to enabling them to update internal processes in alignment with the CTIS.

 

While large pharma companies have established task forces to prepare themselves and have been more involved in EMA training, many smaller and mid-sized companies are turning to partners for help in establishing correct user roles and internal training and updating their processes so that they’re aligned with the activities in the CTIS.

 

As they gear up for CTIS, it would be advisable for companies to plan their transitional trials, and prepare for issues that are likely to be time-consuming, including the manual upload of documents – both for publication and those that won’t be published. They should also be prepared for the likelihood that documents previously submitted via the directive may require changes or additions in order to comply with the regulations.

 

One other important step will be to ensure the company is registered in the Organisation Management Services (OMS) data management service of the SPOR, because CTIS connects to the SPOR database.

 

In all ways, CTIS and the CTR will require companies to be more organized and have people to drive the overall process.

 

Phlexglobal, a leading technology and services organization for clinical and regulatory solutions, is conducting a survey into how well-prepared companies are for the CTIS. In January this year, Phlexglobal merged with PharmaLex. To understand your own preparedness, we encourage you to take  the Phlexglobal survey.

 

About the authors:

Milena Shuytsova-Mircheva is Senior Manager Regulatory Affairs at PharmaLex with extensive experience in life cycle management and clinical trials. Lisa Pascoe is Director of Regulatory Affairs at PharmaLex and the International Services Lead for clinical trial applications, overseeing inquiries, projects and resources.

You can read the blog on Pharmalex's website here.

Topics: eCTD, RIM / IDMP

Clinical Trials & the TMF 101 - Blog 4: The TMF Trinity

Introduction We have been on a journey you and me, we started off by understanding the purpose of a clinical trial and ...

Read More

Clinical Trials & the TMF 101 - Blog 3: Paper vs Electronic, why it is more than a DMS

Introduction Awww it warms my heart you came back to read the third blog. I hope you are finding these helpful, don’t ...

Read More

Clinical Trials & the TMF 101 - Blog 2: What is this TMF you speak of?

Introduction You came back, great! I hope you enjoyed our first blog in this series which was all about the basics of a ...

Read More

Clinical Trials and the TMF 101 - Blog 1: Basics of a Clinical Trial

Introduction  Firstly, welcome, it is great to see you here. Thank you for taking the time to check out our new blog ...

Read More

FDA and MHRA Say Remote and Hybrid Inspections to Continue

At the 2022 Drug Information Association Annual Meeting, held in-person in Chicago June 20-23, representatives from the ...

Read More

Examining the Why and How of Integrating Your eTMF and CTMS

Adapted from a Phlexglobal Ask An Expert interactive discussion held May 11, 2022 and available on-demand here.  

Read More

Subscribe To Our Blog!


Digital Brain Header Large Brain Right

It's time to raise your standard 

CONTACT PHLEXGLOBAL TODAY
 
Contact Us